Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Jan;18(1):76-80.
doi: 10.1080/08998280.2005.11928037.

Ximelagatran (Exanta): alternative to warfarin?

Christy Vaughan  1
Affiliations

Ximelagatran (Exanta): alternative to warfarin?

Christy Vaughan. Proc (Bayl Univ Med Cent). 2005 Jan.
No abstract available

PubMed Disclaimer

References

    1. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res. 2003;109(Suppl 1):S9–S15. - PubMed
    1. Eriksson UG, Bredberg U, Gislen K, Johansson LC, Frison L, Ahnoff M, Gustafsson D. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol. 2003;59:35–43. - PubMed
    1. Food and Drug Administration. Cardiovascular and Renal Drugs Advisory Committee; notice of meeting. Federal Register. 2004 (August 10);69(153):48509–48510. Available at http://www.fda.gov/OHRMS/DOCKETS/98fr/04-18166.htm; accessed October 13, 2004.
    1. Wahlander K, Lapidus L, Olasson C, Thuresson A, Eriksson U, Larson G, Eriksson H. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res. 2002;107:93–99. - PubMed
    1. Gustafsson D, Nystrom J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K, Ungell A, Sorensen H, Nagard S, Abrahamsson A, Bylund R. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res. 2001;101:171–181. - PubMed

LinkOut - more resources